Manish K Jha1, Abu Minhajuddin2, Bharathi S Gadad1, Tracy Greer1, Bruce Grannemann1, Abigail Soyombo1, Taryn L Mayes1, A John Rush3, Madhukar H Trivedi4. 1. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States. 2. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States. 3. Professor Emeritus, Duke-National University of Singapore, Singapore. 4. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, United States. Electronic address: madhukar.trivedi@utsouthwestern.edu.
Abstract
OBJECTIVE: Currently, no valid measures inform treatment selection for depressed patients. Whether C-reactive protein (CRP) in particular and two other acute phase reactants (inflammatory markers) could differentiate between patients responding to either of two treatments with different mechanisms of action was assessed. METHOD: Subjects included Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants randomly assigned to either escitalopram plus placebo (SSRI monotherapy, n=51) or bupropion plus escitalopram combination (bupropion-SSRI combination, n=55) with baseline plasma samples. CRP, serum amyloid P component, and alpha-2-macroglobulin were measured using the Bioplex Pro™ human acute-phase 4-plex panel. We conducted mixed model analyses of depressive symptom (Quick Inventory of Depressive Symptomatology Self-Report) and side-effect burden (Frequency, Intensity, and Burden of Side-Effects Rating Scale) obtained weekly or every other week over the 12-week acute-phase of CO-MED trial to evaluate the relationship between these outcomes and baseline CRP and other acute-phase reactants. RESULTS: The treatment arms did not differ in depressive symptom or side effect outcomes. Most participants (69.8%, 74/106) had baseline CRP levels greater than 1mg/L (indicative of systemic inflammatory activity). Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). The overall remission rate was 41.5%. The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for <1mg/L and Bupropion-SSRI for ≥1mg/L) was 53.1%, with a number needed to treat of 8.6. Side effect burden was unrelated to any baseline inflammatory marker. CONCLUSIONS:Baseline CRP levels relate differentially to antidepressant treatment outcomes in persons with major depressive disorder. Clinicaltrials.gov identifier: NCT00590863.
RCT Entities:
OBJECTIVE: Currently, no valid measures inform treatment selection for depressedpatients. Whether C-reactive protein (CRP) in particular and two other acute phase reactants (inflammatory markers) could differentiate between patients responding to either of two treatments with different mechanisms of action was assessed. METHOD: Subjects included Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants randomly assigned to either escitalopram plus placebo (SSRI monotherapy, n=51) or bupropion plus escitalopram combination (bupropion-SSRI combination, n=55) with baseline plasma samples. CRP, serum amyloid P component, and alpha-2-macroglobulin were measured using the Bioplex Pro™ human acute-phase 4-plex panel. We conducted mixed model analyses of depressive symptom (Quick Inventory of Depressive Symptomatology Self-Report) and side-effect burden (Frequency, Intensity, and Burden of Side-Effects Rating Scale) obtained weekly or every other week over the 12-week acute-phase of CO-MED trial to evaluate the relationship between these outcomes and baseline CRP and other acute-phase reactants. RESULTS: The treatment arms did not differ in depressive symptom or side effect outcomes. Most participants (69.8%, 74/106) had baseline CRP levels greater than 1mg/L (indicative of systemic inflammatory activity). Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). The overall remission rate was 41.5%. The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for <1mg/L and Bupropion-SSRI for ≥1mg/L) was 53.1%, with a number needed to treat of 8.6. Side effect burden was unrelated to any baseline inflammatory marker. CONCLUSIONS: Baseline CRP levels relate differentially to antidepressant treatment outcomes in persons with major depressive disorder. Clinicaltrials.gov identifier: NCT00590863.
Authors: Jeffrey M Greeson; David R Gettes; Sergei Spitsin; Benoit Dubé; Tami D Benton; Kevin G Lynch; Steven D Douglas; Dwight L Evans Journal: Biol Psychiatry Date: 2015-11-10 Impact factor: 13.382
Authors: Richard C Shelton; Michael Falola; Li Li; John Zajecka; Maurizio Fava; George I Papakostas Journal: J Psychiatr Res Date: 2015-09-03 Impact factor: 4.791
Authors: R Strawbridge; D Arnone; A Danese; A Papadopoulos; A Herane Vives; A J Cleare Journal: Eur Neuropsychopharmacol Date: 2015-06-20 Impact factor: 4.600
Authors: John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Rudolf Uher; Katherine E Tansey; Tracy Dew; Wolfgang Maier; Ole Mors; Joanna Hauser; Mojca Zvezdana Dernovsek; Neven Henigsberg; Daniel Souery; Anne Farmer; Peter McGuffin Journal: Am J Psychiatry Date: 2014-10-31 Impact factor: 18.112
Authors: Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Patrick J McGrath; Ahsan Y Khan; Madhukar H Trivedi; Jonathan W Stewart; David W Morris; Stephen R Wisniewski; Sachiko Miyahara; Andrew A Nierenberg; Maurizio Fava; A John Rush Journal: J Clin Psychiatry Date: 2008-11-18 Impact factor: 4.384
Authors: A S Brown; A Sourander; S Hinkka-Yli-Salomäki; I W McKeague; J Sundvall; H-M Surcel Journal: Mol Psychiatry Date: 2013-01-22 Impact factor: 15.992
Authors: Emily S Miller; Denada Hoxha; Emily Pinheiro; William A Grobman; Katherine L Wisner Journal: Arch Womens Ment Health Date: 2018-04-13 Impact factor: 3.633
Authors: Manish K Jha; Abu Minhajuddin; Cherise Chin-Fatt; Tracy L Greer; Thomas J Carmody; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2019-03-20 Impact factor: 4.791
Authors: Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne Journal: Brain Behav Immun Date: 2018-06-19 Impact factor: 7.217
Authors: Bharathi S Gadad; Manish K Jha; Bruce D Grannemann; Taryn L Mayes; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2017-05-26 Impact factor: 4.791
Authors: Daniel C McFarland; Devika R Jutagir; Barry Rosenfeld; William Pirl; Andrew H Miller; William Breitbart; Christian Nelson Journal: Psychooncology Date: 2019-05-15 Impact factor: 3.894
Authors: Bharathi S Gadad; Manish K Jha; Andrew Czysz; Jennifer L Furman; Taryn L Mayes; Michael P Emslie; Madhukar H Trivedi Journal: J Affect Disord Date: 2017-07-05 Impact factor: 4.839